Similar articles

• Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.

  Brugaletta S, Burzotta F, Trani C, Todaro D, Talarico G, Porto I, Leone AM, Niccoli G, Mazzari MA, Mongiardo R, Schiavoni G, Crea F. Brugaletta S, et al. Minerva Cardioangiol. 2008 Feb;56(1):35-42. Minerva Cardioangiol. 2008. PMID: 18432167 Clinical Trial.
• Two-year (mid-term) results for unprotected left main coronary artery percutaneous interventions with drug-eluting stents.

  Yarkoni A, Brodsky A, Sabapathy R, Pershad A. Yarkoni A, et al. Indian Heart J. 2008 May-Jun;60(3):195-9. Indian Heart J. 2008. PMID: 19240306
• Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.

  Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A; LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators. Mehilli J, et al. J Am Coll Cardiol. 2009 May 12;53(19):1760-8. doi: 10.1016/j.jacc.2009.01.035. J Am Coll Cardiol. 2009. PMID: 19422982 Clinical Trial.
• Understanding the drug-eluting stent trials.

  Coolong A, Kuntz RE. Coolong A, et al. Am J Cardiol. 2007 Sep 3;100(5A):17K-24K. doi: 10.1016/j.amjcard.2007.06.004. Epub 2007 Jun 26. Am J Cardiol. 2007. PMID: 17719349 Review.
• Drug-eluting stents: preventing restenosis.

  Slavin L, Chhabra A, Tobis JM. Slavin L, et al. Cardiol Rev. 2007 Jan-Feb;15(1):1-12. doi: 10.1097/01.crd.0000200844.16899.fc. Cardiol Rev. 2007. PMID: 17172878 Review.